DOCSLIB.ORG

Negatively Regulated by ADAM15 TRIF-Mediated TLR3 and TLR4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

TRIF-Mediated TLR3 and TLR4 Signaling Is Negatively Regulated by ADAM15 Suaad Ahmed, Ashwini Maratha, Aisha Qasim Butt, Enda Shevlin and Sinead M. Miggin This information is current as of September 27, 2021. J Immunol 2013; 190:2217-2228; Prepublished online 30 January 2013; doi: 10.4049/jimmunol.1201630 http://www.jimmunol.org/content/190/5/2217 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/01/30/jimmunol.120163 Material 0.DC1 References This article cites 57 articles, 20 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/190/5/2217.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology TRIF-Mediated TLR3 and TLR4 Signaling Is Negatively Regulated by ADAM15 Suaad Ahmed, Ashwini Maratha, Aisha Qasim Butt, Enda Shevlin, and Sinead M. Miggin TLRs are a group of pattern-recognition receptors that play a crucial role in danger recognition and induction of the innate immune response against bacterial and viral infections. The TLR adaptor molecule, Toll/IL-1R domain-containing adaptor inducing IFN (TRIF), facilitates TLR3 and TLR4 signaling and concomitant activation of the transcription factors, NF-kB and IFN regulatory factor 3, leading to proinflammatory cytokine production. Whereas numerous studies have been undertaken toward understand- ing the role of TRIF in TLR signaling, little is known about the signaling components that regulate TRIF-dependent TLR signaling. To this end, TRIF-interacting partners were identified by immunoprecipitation of the TRIF signaling complex, followed by protein identification using liquid chromatography mass spectrometry. Following stimulation of cells with a TLR3 or TLR4 ligand, we identified a disintegrin and metalloprotease (ADAM)15 as a novel TRIF-interacting partner. Toward the functional Downloaded from characterization of the TRIF:ADAM15 interaction, we show that ADAM15 acts as a negative regulator of TRIF-mediated NF-kB and IFN-b reporter gene activity. Also, suppression of ADAM15 expression enhanced polyriboinosinic polyribocytidylic acid and LPS-mediated proinflammatory cytokine production via TRIF. In addition, suppression of ADAM15 expression enhanced rhino- virus 16 and vesicular stomatitis virus–mediated proinflammatory cytokine production. Interestingly, ADAM15 mediated the proteolytic cleavage of TRIF. Thus, ADAM15 serves to curtail TRIF-dependent TLR3 and TLR4 signaling and, in doing so, protects the host from excessive production of proinflammatory cytokines and matrix metalloproteinases. In conclusion, to our http://www.jimmunol.org/ knowledge, our study clearly shows for the first time that ADAM15 plays an unexpected role in TLR signaling, acting as an anti- inflammatory molecule through impairment of TRIF-mediated TLR signaling. The Journal of Immunology, 2013, 190: 2217–2228. he innate immune response is highly conserved and rep- of the MyD88-dependent and TRIF-dependent pathways. Whereas resents the first line of defense against microbial path- MyD88 is used by TLR2, TLR5, TLR7, TLR8, and TLR9, TRIF T ogens (1). The TLR family is a conserved component of is used by TLR3. Both the MyD88 and TRIF-dependent path- the innate immune system that responds to specific pathogen- ways are used by TLR4 toward the induction of proinflammatory associated molecular pattern from viruses, bacteria, fungi, and cytokines and IFN-stimulated genes (5). Additionally, activation parasites (2, 3). Signaling through TLRs can be broadly divided of the TLR pathway also leads to the induction of matrix metal- by guest on September 27, 2021 into two pathways that are linked to downstream activation of loproteinases (MMPs), including MMP-9 (gelatinase B) and NF-kB, MAPKs, and IFN regulatory factors (IRFs) (4). All TLRs MMP-10 (stromelysin 2) (6, 7). Activation of MMPs has been have a Toll/IL-1R domain that facilitates their interaction with associated with the maintenance of normal homeostasis, and the TLR adaptor proteins, five of which have been identified to date, upregulation of MMPs has been linked with inflammatory re- namely MyD88, MyD88 adaptor-like, Toll/IL-1R domain- sponses, cancer, and arthritis (7). containing adaptor inducing IFN (TRIF), TRIF-related adaptor During TLR3 and TLR4 signaling, TRIF, in association with molecule (TRAM), and Sterile-alpha and Armadillo motif-con- TRAM in the case of TLR4, initiates a signaling pathway through taining protein (SARM) (4); these adaptors facilitate activation TRAF3, TANK-binding kinase 1 (TBK1), and inhibitor of nuclear factor-kB(IkB)–kinase complex [IKKε]), which mediates the direct phosphorylation of IRF3 and IRF7 and the formation of Immune Signaling Group, Institute of Immunology, Department of Biology, National IRF3 and IRF7 hetero- or homodimers. The IRF3/7 dimers then University of Ireland Maynooth, Maynooth, County Kildare, Ireland translocate to the nucleus, in association with transcriptional Received for publication June 13, 2012. Accepted for publication December 21, coactivators, such as CBP and p300, and bind to target sequences 2012. in DNA, such as IFN-stimulated response elements (8, 9). Also, This work was supported by the Science Foundation of Ireland. the IRFs, together with the transcription factors ATF-2/c-Jun and Address correspondence and reprint requests to Dr. Sinead M. Miggin, Immune Signaling Group, Institute of Immunology, Department of Biology, National Univer- NF-kB from the IFN-b enhanceosome, bind to a nucleosome-free sity of Ireland Maynooth, Maynooth, County Kildare, Ireland. E-mail address: enhancer region within the IFN-b promoter upstream of the [email protected] transcription start site, leading to transcriptional activation of the The online version of this article contains supplemental material. IFN-b gene (10). The enhancer itself is divided into four positive Abbreviations used in this article: ADAM, a disintegrin and metalloprotease; regulatory domains (PRD) whereby NF-kB binds to the PRDII esiRNA, endoribonuclease-prepared siRNA; HA, hemagglutinin; IRF, IFN regulatory element within the IFN-b enhancer region, ATF-2/c-Jun binds to factor; LC-MS, liquid chromatography mass spectrometry; MEF, murine embryonic fibroblast; MDA5, melanoma differentiation–associated protein 5; MMP, matrix met- the PRDIV element and is activated by JNK, and IRF3 and IRF7 alloproteinase; poly(I:C), polyriboinosinic polyribocytidylic acid; PRD, positive reg- bind to the PRDI-III element (8). Also, TRIF-dependent activation ulatory domain; RGD, arginine-glycine-aspartic acid; RLR, RIG-I–like receptor; RV, rhinovirus; siRNA, small interfering RNA; TBK1, TANK-binding kinase 1; of NF-kB occurs through binding of TRAF6 to TRIF and subse- TRAM, Toll/IL-1R domain-containing adaptor inducing IFN–related adaptor quent ubiquitination-dependent recruitment and activation of molecule; TRIF, Toll/IL-1R domain-containing adaptor inducing IFN; VSV, TAK1 (11). Despite the numerous studies that have been under- vesicular stomatitis virus; WT, wild-type. taken toward understanding the role of TRIF in TLR signaling, Copyright Ó 2013 by The American Association of Immunologists, Inc. 0022-1767/13/$16.00 little is known about the signaling components that regulate the www.jimmunol.org/cgi/doi/10.4049/jimmunol.1201630 2218 TRIF-MEDIATED TLR SIGNALING IS INHIBITED BY ADAM15 dependent TLR signaling pathway. In this study, we sought to medium was supplemented with blasticidin (100 mg/ml). The HEK293-Blue identify novel components of the TRIF signaling pathway. To this IFN-ab culture medium was supplemented with zeocin (100 mg/ml) and end, TRIF-interacting partners were identified by immunoprecip- blasticidin (10 mg/ml). HEK293-TLR9 was as described (18). U373-CD14 cells were cultured in RPMI 1640 with GlutaMAX (Life Technologies-BRL) itation of the TRIF signaling complex, followed by protein iden- supplemented with 10% FBS, 1% penicillin-streptomycin, 1% fungizone, tification using liquid chromatography mass spectrometry (LC- and 250 mg/ml gentamicin (G418; Sigma-Aldrich). Highly purified protein- MS). Following stimulation of cells with a TLR3 or TLR4 li- free LPS derived from Escherichia coli strain 011:B4 (Alexis) and naked gand, we identified a disintegrin and metalloprotease (ADAM)15 poly(I:C) (InvivoGen) were used for all treatments. ADAM15 small inter- fering RNA (siRNA) was purchased from Sigma-Aldrich (catalog as a novel TRIF-interacting partner. ADAM15, also known as EHU076821) and siRNA control from Ambion (catalog AM16106). RV16 metalloprotease–arginine-glycine-aspartic acid (RGD)–disintegrin was from S. Goodbourn (University of London). VSV was from American protein (Metargidin), is a type I transmembrane glycoprotein be-
Recommended publications
  • What Are the Roles of Metalloproteinases in Cartilage and Bone Damage? G Murphy, M H Lee

    What Are the Roles of Metalloproteinases in Cartilage and Bone Damage? G Murphy, M H Lee

    iv44 Ann Rheum Dis: first published as 10.1136/ard.2005.042465 on 20 October 2005. Downloaded from REPORT What are the roles of metalloproteinases in cartilage and bone damage? G Murphy, M H Lee ............................................................................................................................... Ann Rheum Dis 2005;64:iv44–iv47. doi: 10.1136/ard.2005.042465 enzyme moiety into an upper and a lower subdomain. A A role for metalloproteinases in the pathological destruction common five stranded beta-sheet and two alpha-helices are in diseases such as rheumatoid arthritis and osteoarthritis, always found in the upper subdomain with a further C- and the irreversible nature of the ensuing cartilage and bone terminal helix in the lower subdomain. The catalytic sites of damage, have been the focus of much investigation for the metalloproteinases, especially the MMPs, have been several decades. This has led to the development of broad targeted for the development of low molecular weight spectrum metalloproteinase inhibitors as potential therapeu- synthetic inhibitors with a zinc chelating moiety. Inhibitors tics. More recently it has been appreciated that several able to fully differentiate between individual enzymes have families of zinc dependent proteinases play significant and not been identified thus far, although a reasonable level of varied roles in the biology of the resident cells in these tissues, discrimination is now being achieved in some cases.7 Each orchestrating development, remodelling, and subsequent family does, however, have other unique domains with pathological processes. They also play key roles in the numerous roles, including the determination of physiological activity of inflammatory cells. The task of elucidating the substrate specificity, ECM, or cell surface localisation (fig 1).
  • ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease

    ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease

    International Journal of Molecular Sciences Review ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease Francesca Tosetti 1,* , Massimo Alessio 2, Alessandro Poggi 1,† and Maria Raffaella Zocchi 3,† 1 Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico S. Martino Largo R. Benzi 10, 16132 Genoa, Italy; [email protected] 2 Proteome Biochemistry, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] 3 Division of Immunology, Transplants and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work as last author. Abstract: Enzymes, once considered static molecular machines acting in defined spatial patterns and sites of action, move to different intra- and extracellular locations, changing their function. This topological regulation revealed a close cross-talk between proteases and signaling events involving post-translational modifications, membrane tyrosine kinase receptors and G-protein coupled recep- tors, motor proteins shuttling cargos in intracellular vesicles, and small-molecule messengers. Here, we highlight recent advances in our knowledge of regulation and function of A Disintegrin And Metalloproteinase (ADAM) endopeptidases at specific subcellular sites, or in multimolecular com- plexes, with a special focus on ADAM10, and tumor necrosis factor-α convertase (TACE/ADAM17), since these two enzymes belong to the same family, share selected substrates and bioactivity. We will discuss some examples of ADAM10 activity modulated by changing partners and subcellular compartmentalization, with the underlying hypothesis that restraining protease activity by spatial Citation: Tosetti, F.; Alessio, M.; segregation is a complex and powerful regulatory tool.
  • Expression of the Disintegrin Metalloprotease, ADAM-10, In

    Expression of the Disintegrin Metalloprotease, ADAM-10, In

    314 Vol. 10, 314–323, January 1, 2004 Clinical Cancer Research Expression of the Disintegrin Metalloprotease, ADAM-10, in Prostate Cancer and Its Regulation by Dihydrotestosterone, Insulin-Like Growth Factor I, and Epidermal Growth Factor in the Prostate Cancer Cell Model LNCaP Daniel R. McCulloch,1 Pascal Akl,1 Conclusions: This study describes for the first time Hemamali Samaratunga,2 Adrian C. Herington,1 the expression, regulation, and cellular localization of and Dimitri M. Odorico1 ADAM-10 protein in PCa. The regulation and membrane 1 localization of ADAM-10 support our hypothesis that Hormone-Dependent Cancer Program, School of Life Sciences, ADAM-10 has a role in extracellular matrix maintenance Queensland University of Technology, Brisbane, Queensland, Australia, and 2Sullivan Nicolaides Pathology, Brisbane, Queensland, and cell invasion, although the potential role of nuclear Australia ADAM-10 is not yet known. INTRODUCTION ABSTRACT The disintegrin metalloproteases ADAMs, like the matrix Purpose: The disintegrin metalloprotease ADAM-10 is metalloproteinases (MMPs), are members of the metzincin a multidomain metalloprotease that is potentially significant (zinc-dependent metalloprotease) superfamily. To date, more in tumor progression due to its extracellular matrix-degrad- than 30 ADAMs have been characterized (1), some of which are ing properties. Previously, ADAM-10 mRNA was detected involved in diverse biological functions such as fertilization, in prostate cancer (PCa) cell lines; however, the presence of neurogenesis (2, 3), and the ectodomain shedding of growth ADAM-10 protein and its cellular localization, regulation, factors such as amyloid precursor protein and tumor necrosis and role have yet to be described. We hypothesized that factor ␣ (4, 5).
  • Conservation and Divergence of ADAM Family Proteins in the Xenopus Genome

    Conservation and Divergence of ADAM Family Proteins in the Xenopus Genome

    Wei et al. BMC Evolutionary Biology 2010, 10:211 http://www.biomedcentral.com/1471-2148/10/211 RESEARCH ARTICLE Open Access ConservationResearch article and divergence of ADAM family proteins in the Xenopus genome Shuo Wei*1, Charles A Whittaker2, Guofeng Xu1, Lance C Bridges1,3, Anoop Shah1, Judith M White1 and Douglas W DeSimone1 Abstract Background: Members of the disintegrin metalloproteinase (ADAM) family play important roles in cellular and developmental processes through their functions as proteases and/or binding partners for other proteins. The amphibian Xenopus has long been used as a model for early vertebrate development, but genome-wide analyses for large gene families were not possible until the recent completion of the X. tropicalis genome sequence and the availability of large scale expression sequence tag (EST) databases. In this study we carried out a systematic analysis of the X. tropicalis genome and uncovered several interesting features of ADAM genes in this species. Results: Based on the X. tropicalis genome sequence and EST databases, we identified Xenopus orthologues of mammalian ADAMs and obtained full-length cDNA clones for these genes. The deduced protein sequences, synteny and exon-intron boundaries are conserved between most human and X. tropicalis orthologues. The alternative splicing patterns of certain Xenopus ADAM genes, such as adams 22 and 28, are similar to those of their mammalian orthologues. However, we were unable to identify an orthologue for ADAM7 or 8. The Xenopus orthologue of ADAM15, an active metalloproteinase in mammals, does not contain the conserved zinc-binding motif and is hence considered proteolytically inactive. We also found evidence for gain of ADAM genes in Xenopus as compared to other species.
  • Antibody Target for Therapeutic Inhibition Of

    Antibody Target for Therapeutic Inhibition Of

    CRT OPPORTUNITY Biological Therapeutics - Target Validation ANTIBODY TARGET FOR THERAPEUTIC INHIBITION OF ADAM8 • ADAM8 is a tractable target with broad utility in oncology and inflammatory indications • Recent study validates ADAM8 as an antibody target in cancer COMMERCIAL OPPORTUNITY A CRT is seeking a collaborative or licensing partner to develop an antibody against the validated target ADAM8 to inhibit activity for cancer therapy. We identified an epitope on ADAM8 (MS2, CD156), where three amino acids are exposed on the outside of the disintegrin domain (Fig 1A). This sequence forms a potential contact surface with several proteins, influencing ADAM8 activity. This epitope was then mimicked by a cyclic peptide and use of this peptide resulted in decreased ADAM8 activity. We now seek collaboration with a partner wanting to develop an inhibitory antibody against the epitope for use in cancer therapy and other ADAM8-related diseases. ADAM8 has been validated as a target by peptide inhibition, several knock-out and knock-down model systems and also by inhibition with commercial tool antibodies binding to the indicated epitope. Inhibition of ADAM8 by our peptide inhibitor BK-1361 comes with data that validates ADAM8 as a cancer target, plus identified targets potentially useful as PD markers. Additionally, there is the opportunity to develop a companion diagnostic. Figure 1: In vivo efficacy of inhibition of breast tumour formation with a commercial tool antibody against ADAM8 (MAb 1031). A) We demonstrated ADAM8 activity as being instrumental The epitope needed for activation of ADAM8. B) and C) show the inhibition of tumour formation and growth in a breast tumour model for tumour development in several indications including using MDA-MB-231 cells injected in the mammary fat pad of female pancreatic cancer [2] and glioma [3].
  • ADAM15 Targets MMP9 Activity to Promote Lung Cancer Cell Invasion

    ADAM15 Targets MMP9 Activity to Promote Lung Cancer Cell Invasion

    ONCOLOGY REPORTS 34: 2451-2460, 2015 ADAM15 targets MMP9 activity to promote lung cancer cell invasion DAN-DAN DONG1, HUI ZHOU2 and GAO LI3 1Department of Pathology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072; 2Department of Thoracic Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013; 3Department of Thoracic Surgery, Hainan General Hospital, Haikou, Hainan 570311, P.R. China Received June 17, 2015; Accepted July 20, 2015 DOI: 10.3892/or.2015.4203 Abstract. ADAM15 is a membrane-associated proteinase bound cell surface glycoproteins (1). These zinc-dependent belonging to a disintegrin and metalloproteinase (ADAM) proteases contain an amino terminal metalloproteinase and a family. Recent studies suggested that ADAM15 is overex- disintegrin domain, a cysteine-rich and an EGF-like sequence, pressed in several types of cancer and is involved in metastatic a transmembrane and a cytoplasmic domain (2). It has been tumor progression. However, the function of ADAM15 in proven that 13 members of ADAM family are catalytically non-small cell lung cancer (NSCLC) is currently unknown. In active through their metalloproteinase domain. These catalytic the present study, we found that high expression of ADAM15 members play an important role in mediating extracellular was associated with decreased overall survival (OS) and matrix protein degradation and shedding of growth factors, disease-free survival (DFS) in NSCLC patients. Furthermore, cytokines and adhesion molecules. Besides, the disintegrin shRNA-mediated knockdown of ADAM15 attenuated cell domain of ADAMs is also involved in binding to integrins migration and invasion. Mechanistic study demonstrated that to mediate cell-cell and cell-matrix interactions (3).
  • Endogenous Regulators of Angiogenesis &#X2013

    Endogenous Regulators of Angiogenesis –

    Cancer and Metastasis Reviews 19: 159–165, 2000. © 2000 Kluwer Academic Publishers. Printed in the Netherlands. Endogenous regulators of angiogenesis – emphasis on proteins with thrombospondin – type I motifs Darren Carpizo and M. Luisa Iruela-Arispe Department of Molecular, Cell and Developmental Biology, Molecular Biology Institute and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA Key words: angiogenesis, thrombospondin, proteins Abstract Angiogenesis has been acknowledged as an important requirement for growth and metastasis of tumors. Complete or partial suppression of vascular growth by a number of different strategies has been consistently associated with suppression of tumor expansion and even reduction of tumor burden. Consequently, identification of the molecular pathways of the angiogenic response has been a major focus of interest in academia and industry. The development of tumor-specific anti-angiogenic therapy was also catalyzed by the finding that inhibitors of angiogenesis appeared immune to the development of drug resistance by the tumor cells, a major restrain in current chemotherapy. Although the full identification of players and their cross-talk is still at its infancy, it appears that partial blockade of one of the steps in the angiogenesis cascade, is sufficient to affect capillary morphogenesis. Thus, suppression of specific integrin pathways or vascular endothelial growth factor signaling have been shown effective in the suppression of tumor-mediated angiogenesis and have led to subsequent initiation of clinical trials. In addition to the generation of antibodies or chemical mimetics to interfere with particular steps during vascular organization, several endogenous (or physiological) molecules have also been identified. The list of endogenous modulators of angiogenesis is growing and can offer additional and important tool for the generation of therapies to restrain tumor vascularization.
  • The Disintegrin/Metalloproteinase ADAM10 Is Essential for the Establishment of the Brain Cortex

    The Disintegrin/Metalloproteinase ADAM10 Is Essential for the Establishment of the Brain Cortex

    The Journal of Neuroscience, April 7, 2010 • 30(14):4833–4844 • 4833 Development/Plasticity/Repair The Disintegrin/Metalloproteinase ADAM10 Is Essential for the Establishment of the Brain Cortex Ellen Jorissen,1,2* Johannes Prox,3* Christian Bernreuther,4 Silvio Weber,3 Ralf Schwanbeck,3 Lutgarde Serneels,1,2 An Snellinx,1,2 Katleen Craessaerts,1,2 Amantha Thathiah,1,2 Ina Tesseur,1,2 Udo Bartsch,5 Gisela Weskamp,6 Carl P. Blobel,6 Markus Glatzel,4 Bart De Strooper,1,2 and Paul Saftig3 1Center for Human Genetics, Katholieke Universiteit Leuven and 2Department for Developmental and Molecular Genetics, Vlaams Instituut voor Biotechnologie (VIB), 3000 Leuven, Belgium, 3Institut fu¨r Biochemie, Christian-Albrechts-Universita¨t zu Kiel, D-24098 Kiel, Germany, 4Institute of Neuropathology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany, 5Department of Ophthalmology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany, and 6Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, and Departments of Medicine and of Physiology, Systems Biology and Biophysics, Weill Medical College of Cornell University, New York, New York 10021 The metalloproteinase and major amyloid precursor protein (APP) ␣-secretase candidate ADAM10 is responsible for the shedding of ,proteins important for brain development, such as cadherins, ephrins, and Notch receptors. Adam10 ؊/؊ mice die at embryonic day 9.5 due to major defects in development of somites and vasculogenesis. To investigate the function of ADAM10 in brain, we generated Adam10conditionalknock-out(cKO)miceusingaNestin-Crepromotor,limitingADAM10inactivationtoneuralprogenitorcells(NPCs) and NPC-derived neurons and glial cells. The cKO mice die perinatally with a disrupted neocortex and a severely reduced ganglionic eminence, due to precocious neuronal differentiation resulting in an early depletion of progenitor cells.
  • A Disintegrin and Metalloprotease 15 Is Expressed on Rheumatoid Arthritis Synovial Tissue Endothelial Cells and May Mediate Angiogenesis

    A Disintegrin and Metalloprotease 15 Is Expressed on Rheumatoid Arthritis Synovial Tissue Endothelial Cells and May Mediate Angiogenesis

    cells Article A Disintegrin and Metalloprotease 15 is Expressed on Rheumatoid Arthritis Synovial Tissue Endothelial Cells and may Mediate Angiogenesis Shinichiro Nishimi, Takeo Isozaki * , Kuninobu Wakabayashi, Hiroko Takeuchi and Tsuyoshi Kasama Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8555, Japan; [email protected] (S.N.); [email protected] (K.W.); [email protected] (H.T.); [email protected] (T.K.) * Correspondence: [email protected]; Tel.: +813(3784)-8942; Fax: +813(3784)-8946 Received: 7 November 2018; Accepted: 5 January 2019; Published: 9 January 2019 Abstract: A disintegrin and metalloprotease 15 (ADAM15) is involved in several malignancies. In this study, we investigated the role of ADAM15 in rheumatoid arthritis (RA) angiogenesis. Soluble ADAM15 (s-ADAM15) in serum from RA and normal (NL) subjects was measured using ELISA. To determine membrane-anchored ADAM15 (ADAM15) expression in RA synovial tissues, immunohistochemistry was performed. To examine the role of ADAM15 in angiogenesis, we performed in vitro Matrigel assays and monocyte adhesion assays using human umbilical vein endothelial cells (HUVECs) transfected with ADAM15 siRNA. Finally, to investigate whether angiogenic mediators were affected by ADAM15, cytokines in ADAM15 siRNA-transfected HUVEC-conditioned medium were measured. ADAM15 was significantly higher in RA serum than in NL serum. ADAM15 was also expressed on RAST endothelial cells. ADAM15 siRNA-treated HUVECs had decreased EC tube formation in response to RA synovial fluids compared with non-treated HUVECs. The adhesion index of ADAM15 siRNA-transfected HUVECs was significantly lower than the adhesion index of control siRNA-transfected HUVECs.
  • Strategies to Target ADAM17 in Disease: from Its Discovery to the Irhom Revolution

    Strategies to Target ADAM17 in Disease: from Its Discovery to the Irhom Revolution

    molecules Review Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution Matteo Calligaris 1,2,†, Doretta Cuffaro 2,†, Simone Bonelli 1, Donatella Pia Spanò 3, Armando Rossello 2, Elisa Nuti 2,* and Simone Dario Scilabra 1,* 1 Proteomics Group of Fondazione Ri.MED, Research Department IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Via E. Tricomi 5, 90145 Palermo, Italy; [email protected] (M.C.); [email protected] (S.B.) 2 Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; [email protected] (D.C.); [email protected] (A.R.) 3 Università degli Studi di Palermo, STEBICEF (Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche), Viale delle Scienze Ed. 16, 90128 Palermo, Italy; [email protected] * Correspondence: [email protected] (E.N.); [email protected] (S.D.S.) † These authors contributed equally to this work. Abstract: For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as the tumor necrosis factor convertase, it has been considered a major drug target, especially in the context of inflammatory diseases and cancer. Nevertheless, the development of drugs targeting ADAM17 has been harder than expected. This has generally been due to its multifunctionality, with over 80 different transmembrane proteins other than tumor necrosis factor α (TNF) being released by ADAM17, and its structural similarity to other metalloproteinases. This review provides an overview of the different roles of ADAM17 in disease and the effects of its ablation in a number of in vivo models of pathological conditions.
  • ADAM15 Supports Prostate Cancer Metastasis by Modulating Tumor Cell–Endothelial Cell Interaction Abdo J

    ADAM15 Supports Prostate Cancer Metastasis by Modulating Tumor Cell–Endothelial Cell Interaction Abdo J

    Research Article ADAM15 Supports Prostate Cancer Metastasis by Modulating Tumor Cell–Endothelial Cell Interaction Abdo J. Najy,1,2 Kathleen C. Day,1 and Mark L. Day1,2 1Department of Urology and 2Program in Cellular and Molecular Biology and University of Michigan, Ann Arbor, Michigan Abstract The less studied ADAM (a disintegrin and metalloproteinase) Using human tumor and cDNA microarray technology, we family of membrane metalloproteinases may also support tumor progression by modulating key physiologic cell surface proteins have recently shown that the ADAM15 disintegrin is signifi- such as membrane-anchored growth factors and their comple- cantly overexpressed during the metastatic progression of mentary receptors, cell adhesion molecules, and integrins (4). The human prostate cancer. In the current study, we used ADAM family is composed of 40 members, of which 13 members lentiviral-based short hairpin RNA (shRNA) technology to are catalytically active. These catalytically active members contain down-regulate ADAM15 in the metastatic prostate cancer cell a metalloproteinase domain that is implicated in growth factor line, PC-3. ADAM15 down-regulation dramatically attenuated shedding and extracellular matrix (ECM) degradation. ADAM17 many of the malignant characteristics of PC-3 cells in vitro has been reported to process pro–tumor necrosis factor (TNF)-a, and prevented the s.c. growth of PC-3 cells in severe combined TNF receptors, interleukin-6 receptor, and amphiregulin (5, 6), immunodeficient (SCID) mice. By inhibiting the expression of and ADAM9, ADAM10, ADAM12, and ADAM17 are believed to ADAM15 in PC-3 cells, we showed decreased cell migration cleave the epidermal growth factor receptor (EGFR) ligand, HB- and adhesion to specific extracellular matrix proteins.
  • Regulation of Profibrotic Responses by ADAM17 Activation in High Glucose Requires Its C-Terminus and FAK Renzhong Li, Tony Wang, Khyati Walia, Bo Gao and Joan C

    Regulation of Profibrotic Responses by ADAM17 Activation in High Glucose Requires Its C-Terminus and FAK Renzhong Li, Tony Wang, Khyati Walia, Bo Gao and Joan C

    © 2018. Published by The Company of Biologists Ltd | Journal of Cell Science (2018) 131, jcs208629. doi:10.1242/jcs.208629 RESEARCH ARTICLE Regulation of profibrotic responses by ADAM17 activation in high glucose requires its C-terminus and FAK Renzhong Li, Tony Wang, Khyati Walia, Bo Gao and Joan C. Krepinsky* ABSTRACT and amphiregulin have been implicated in the pathogenesis of Glomerular matrix accumulation is the hallmark of diabetic diabetic kidney disease (Kefaloyianni et al., 2016; Melenhorst et al., nephropathy. The metalloprotease ADAM17 mediates high glucose 2009; Uttarwar et al., 2011). Cleavage of the renoprotective (HG)-induced matrix production by kidney mesangial cells through exopeptidase ACE2 by ADAM17 is also thought to contribute to release of ligands for the epidermal growth factor receptor. Here, diabetic kidney tubular injury (Salem et al., 2014). In diabetic mice, we study the mechanism by which HG activates ADAM17. We find a nonselective metalloprotease inhibitor decreased glomerular that the C-terminus is essential for ADAM17 activation and the sclerosis, although effects cannot be specifically attributed to profibrotic response to HG. In the C-terminus, Src-mediated Y702 inhibition of ADAM17 (Ford et al., 2013). More specific ADAM17 phosphorylation and PI3K–MEK–Erk-mediated T735 phosphorylation inhibitors, however, have been associated with adverse effects, are crucial for ADAM17 activation, both are also required for the preventing their long-term use in the treatment of diabetic HG-induced increase in cell surface